Haemonetics stock: Citizens raises target to USD 144
Published on 11/17/2026 at 00:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst raises outlook
- Citizens kept an Outperform rating after citing strength across Haemonetics' Apheresis and MedSurg businesses.
- The analyst highlighted market share gains, global collections growth, product utilization and CSL's return as a customer.
- Haemonetics is due to present at the Jefferies Global Healthcare Conference on November 18-19, 2026.
Citizens raised its price target for Haemonetics from USD 115 to USD 144 on November 16, 2026, while maintaining an Outperform rating. In a report carried by Markets Insider, the analyst cited broad-based strength across Haemonetics' Apheresis and MedSurg businesses.
The note pointed to market share gains, global collections growth and increased product utilization. It also cited CSL's return as a customer and Haemonetics' raised fiscal growth outlook as supports for the revised view.
Growth drivers remain in focus
The analyst's assessment keeps attention on the company's plasma-related activities and its medical-surgical portfolio. For investors, the next question is whether customer activity and product utilization can sustain the stronger growth expectations while the business expands its installed base.
Haemonetics is scheduled to participate in the Jefferies Global Healthcare Conference in London on November 18-19, 2026, according to its investor relations page.
Healthcare technology portfolio
Haemonetics is a global healthcare company that develops medical products and solutions aimed at improving patient care and reducing healthcare costs. Its portfolio addresses blood and plasma component collection, the surgical suite and hospital transfusion services. The company is headquartered in the United States and operates across these healthcare markets.
Haemonetics company facts
- Company: Haemonetics Corporation
- ISIN: US4050241003
- Ticker: HAE
- Home exchange: NYSE
- Sector: Healthcare technology
The broader market backdrop is covered by the S&P 500.
